WO 03/078967 PCT/US03/08259

WHAT IS CLAIMED IS:

1	1.	An isolated stem cell sustainable in culture under glycolytic conditions			
2	and which maintains the potential to differentiate.				
1	2.	The stem cell of claim 1 which is unipotent or pluripotent.			
1	3.	The stem cell of claim 1 which is an embryonic or somatic stem cell.			
1	4.	The stem cell of claim 3 which is a pluripotent cell from a			
2	preimplantation embryo.				
1	5.	The stem cell of claim 1 which is a primordial germ cell.			
1	6.	The stem cell of claim 1 selected from the group consisting of			
2	hematopoietic, neuronal and mesenchymal stem cells.				
1	7.	An isolated stem cell which cell shows characteristic green staining			
2	with the mitochondrial marker JC-1.				
1	8.	An isolated stem cell which cell displays a low mitochondrial inner			
2	membrane potential b	pased upon JC-1 green staining.			
1	9.	An isolated stem cell which cell displays a high mitochandrial inner			
2	9. An isolated stem cell which cell displays a high mitochondrial inner membrane potential based upon JC-1 red staining.				
_					
1	10.	A method of isolating a stem cell, comprising the steps of:			
2	(a)	isolating a blastocyst;			
3	(b)	identifying those cells which rely upon glycolysis for survival;			
4	(c)	isolating a glycolytic cell from the inner cell mass of the blastocyst;			
5	and				
6	(d)	culturing the isolated glycolytic cell to obtain an isolated stem cell.			
1	11.	The method of claim 10, wherein the cells are identified by staining			
2	with the mitochondrial marker JC-1.				
1	12.	The method of claim 10, further comprising maintaining the isolated			
2	cells on a fibroblast feeder layer to prevent differentiation.				

WO 03/078967 PCT/US03/08259

1	13.	A chimeric animal produced from a cell of claims 1 or 9.				
1	14.	A method of producing a chimeric animal comprising				
2	(a)	isolating a blastocyst;				
3	(b)	identifying those cells which rely upon glycolysis for survival;				
4	(c)	isolating the glycolytic cells from the inner cell mass of the blastocyst;				
5	(d)	transfecting a desired gene into the glycolytic cells;				
6	(e)	injecting the transfected cells into recipient blastocysts;				
7	(f)	implanting the transformed blastocysts into a host uterus; and				
8	(g)	nurturing the blastocysts to develop to term.				
1	15.	A method of producing glycolytic-dependent cells, comprising the				
2	steps of:					
3	(a)	culturing cells under hypoxic conditions;				
4	(b)	identifying those cells which rely upon glycolysis for survival;				
5	(c)	isolating the glycolytic cells from the culture; and				
6	(d)	culturing the isolated glycolytic cells.				
1	16.	A stem cell of claims 1 or 9 which is a mammalian stem cell.				
1	17.	A chimeric mammal produced from a stem cell of claim 16.				
1	18.	An isolated stem cell, wherein said stem cell can be identified by				
2	staining said cell with the fluorescent dye JC-1.					
1	19.	The isolated stem cell of claim 18, wherein said cell is sensitive to				
2	inhibitors of multidrug resistance (MDR) targets.					
1	20.	The isolated stem cell of claim 19, wherein said inhibitors are selected				
2	from the group consisting of verapamil, reserpine, and cyclosporine A.					
1	21.	The isolated stem cell of claim 19, wherein the multidrug resistance				
2	(MDR) target is an MDR-like dye efflux pump.					
1	22.	A method of identifying functionally distinct stem cells, comprising:				
2		(a) staining the cells with the fluorescent dye JC-1;				

WO 03/078967 PCT/US03/08259

3		(b)	sorting the stained cells by fluorescence activated cell sorting			
4	(FACS);					
5		(c)	analyzing said functionally distinct stem cells by comparing			
6	their sensitivity to inhibitors of multidrug resistance (MDR) targets; and					
7		(d)	identifying a MDR-inhibitor sensitive JC-1 subpopulation of			
8	cells.					
1	23.	The M	DR-inhibitor sensitive JC-1 subpopulation of claim 22, wherein			
2	said subpopulation has an increased differentiation permissiveness.					
3						
1	24.	A meth	nod of switching embryonic stem cells between two			
2	subpopulations, comprising:					
3		a) expo	osing a JC-1 green subpopulation to inhibitors of multidrug			
4	resistance genes; and					
5		b) over	rexpressing recombinant multidrug resistance genes in a JC-1			
6	red subpopulation.					
7						
1	25.	The m	ethod of claim 24, wherein said inhibitors are selected from the			
2	group consisting of verapamil, reserpine and cyclosporine.					
1	26.	A metl	nod of changing a cell's ability to differentiate by switching the			
2	subpopulations of claim 24.					
1	27.	An em	bryonic stem cell which is differentiated by the method of claim			
2	24.					
3						